November 7, 2022
PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
PA-20-200 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
PA-20-188 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)
PA-20-190 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)
PAR-21-208 - Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)
PA-21-049 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)
PA-21-050 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)
PA-21-051 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)
PA-21-052 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)
PA-21-048 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)
National Institute on Drug Abuse (NIDA)
The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in supporting basic research on the application of chemoproteomic approaches for the discovery of targets and for development of drugs to treat addiction and substance use disorders.
Chemoproteomics combines diverse approaches in synthetic chemistry, cell biology and mass spectrometry to covalently modify, identify, and characterize protein targets of interest for drug discovery. Chemical proteomic platforms such as the activity-based protein profiling (ABPP) have proven effective for identifying drug targets in various biological settings. Use of reactivity-based chemical probes and advanced quantitative mass spectrometry-based proteomic techniques have enabled identification of hotspots for ligand binding on proteins including those that are generally considered undruggable. Chemoproteomic methods also enable identification of allosteric binding sites that could be targeted with small molecules to modulate the function of the target proteins. These chemoproteomic approaches, together with emerging technologies such as targeted protein degradation, covalent fragment-based ligand discovery, and biorthogonal chemistry, are transforming the landscape of drug discovery. Development of novel chemoproteomic methods and their application, therefore, holds considerable potential for identifying and illuminating targets of relevance to substance use and for providing leads for the development of drugs for treating substance use disorders.
The goal of this announcement is to encourage preclinical research aimed at developing and applying chemoproteomic approaches to identify targets of relevance to substance use disorders and to develop novel pharmacological tools, methods, and therapeutic interventions for the treatment of substance use disorders and addiction. Examples of research areas of interest include, but are not limited to:
Application and Submission Information
This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026.
Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this notice.
All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:
Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.
National Institute on Drug Abuse (NIDA)